insights_auto
Why is ABVX down 3,67%?
Dive Deeperchevron_right
ABVX:EPA
Abivax SA
78,70 €
arrow_downward
-3,67%(-3,00) 1D
23-окт., 16:35:27 GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ABVX...
Open
80,90 €
High
81,15 €
Low
78,05 €
Mkt. cap
6,82 млд
Avg. vol.
124,60 миң
Volume
74,87 миң
52-wk high
139,00 €
52-wk low
60,45 €
EPS
-5,20 €
Shares outstanding
87,55 млн
No. of employees
98
Open
80,90 €
High
81,15 €
Low
78,05 €
Mkt. cap
6,82 млд
Avg. vol.
124,60 миң
Volume
74,87 миң
52-wk high
139,00 €
52-wk low
60,45 €
EPS
-5,20 €
Shares outstanding
87,55 млн
No. of employees
98
News stories
From web sources and news partners
Yahoo Finance
·
31 мүнөт мурун
3 AI Stocks That Can Beat the Nasdaq Composite in 2027
Stocktwits
·
59 мүнөт мурун
Michael Burry Says S&P 500 Looks ‘Uncannily Close’ To 2000 — And ‘Busted’ Stocks Could Be The Winners
WSJ
·
1 күн мурун
Stocks Pulled in Two Directions, Fall to End Volatile Week
Yardeni QuickTakes
·
6 саат мурун
US MARKETS CALL: Still Proceeding Cautiously
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Employees98
Founded2013-ж., 4-дек.
Headquarters-
Sector-
Websiteabivax.com